AstraZeneca announced Monday that the FDA has approved the use of its Imfinzi immunotherapy for the treatment of advanced or recurrent endometrial cancer.

The biopharmaceutical company points out that the green light from the US health authority relates more specifically to endometrial cancer characterized by a failure of the DNA repair system (dMMR).

AstraZeneca points out that endometrial cancer is currently the fourth most common cancer among women in the United States, with 66.000 cases diagnosed each year and nearly 12,000 deaths.

In individuals with advanced disease, the five-year survival rate is currently less than 20%.

In a press release, AstraZeneca states that the FDA approval follows a Phase III clinical trial showing a 58% reduction in disease progression or death in patients treated with Imfinzi.

Copyright (c) 2024 CercleFinance.com. All rights reserved.